

CITATION REPORT

List of articles citing

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

DOI: 10.1016/s0140-6736(01)05623-9
Lancet, The, 2001, 358, 455-60.

Source: <https://exaly.com/paper-pdf/32478070/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
203	Do anti-inflammatories have a role in AD therapy?. 2001 , &NA;, 9		
202	Current Awareness in human psychopharmacology. 2001 , 16, 647-656		
201	Current Awareness. 2001 , 16, 1111-1118		1
200	An inflammatory drug prospect. 2001 , 414, 159-60		34
199	Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease?. 2001 , 345, 1567-8		57
198	Anti-Aging Medicine LiteratureWatch. 2001 , 4, 389-410		
197	Drug treatment of Alzheimer's disease. 2002 , 12, 165-173		
196	Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence. 2002 , 24, 248-68		46
195	Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. 2002 , 59, 880-6		275
194	Current World Literature. 2002 , 15, 499-518		
193	Pharmacotherapy for Alzheimer's disease and other dementias. 2002 , 15, 403-409		3
192	Current World Literature. 2002 , 15, 313-340		
191	Cognitive pharmacotherapy of Alzheimer's disease and other dementias. 2002 , 47, 715-22		6
190	Antioxidants as treatment for neurodegenerative disorders. 2002 , 11, 1407-35		169
189	Is pharmacological prevention of Alzheimer's a realistic goal?. 2002 , 3, 365-80		13
188	Inflammation in neurodegenerative disease--a double-edged sword. 2002 , 35, 419-32		927
187	Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. 2002 , 23, 324-30		59

186	Alzheimer's disease: targets for drug development. 2002 , 2, 1-9	8
185	The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. 2002 , 1, 279-84	163
184	Neuroinflammation in Alzheimer's disease and prion disease. 2002 , 40, 232-9	366
183	Development of antiinflammatory therapy for Alzheimer's disease. 2002 , 56, 421-427	4
182	Anti-inflammatory agents in Alzheimer's disease. 2002 , 2, 405-9	16
181	NSAID and Alzheimer's disease; possible answers and new questions. 2002 , 7, 925-6	8
180	Dementie: ziekte of veroudering?. 2002 , 6, 140-145	
179	Local neuroinflammation and the progression of Alzheimer's disease. 2002 , 8, 529-38	204
178	Anti-inflammatory therapy in Alzheimer's disease: is hope still alive?. 2003 , 250, 788-92	57
177	Treatment of Alzheimer's disease: current status and new perspectives. 2003 , 2, 539-47	590
176	Stress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders. 2003 , 97, 35-53	51
175	Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. 2003 , 137, 32-41	96
174	The in vivo use of chloroquine to promote non-viral gene delivery to the liver via the portal vein and bile duct. 2003 , 5, 209-18	43
173	Chloroquine induces activation of nuclear factor-kappaB and subsequent expression of pro-inflammatory cytokines by human astroglial cells. 2003 , 84, 1266-74	39
172	Stroke, dementia, and drug delivery. 2004 , 57, 15-26	8
171	Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. 2003 , 50, 39-47	127
170	Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. 2003 , 63, 731-9	48
169	A neural complexity measure applied to MEG data in Alzheimer's disease. 2003 , 114, 1034-40	54

168	2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. 2003 , 5, 404-17	80
167	Inflammatory processes in Alzheimer's disease. 2003 , 27, 741-9	372
166	In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile. 2003 , 117, 723-30	161
165	Nonsteroidal anti-inflammatory drugs and Alzheimer disease: what's next?. 2003 , 289, 2865-7	25
164	Alzheimer's disease: from molecular pathogenesis to innovative therapies. 2003 , 3, 619-30	7
163	Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. 2003 , 289, 2819-26	693
162	Scintigraphic visualization of inflammation in neurodegenerative disorders. 2003 , 24, 209-21	7
161	Current World Literature. 2003 , 6, 109-125	
160	Prediction of the rate of decline in cognitive function in Alzheimer's disease: a model based on simple demographic data and widely used rating scales. 2003 , 16, 276-82	4
159	NSAIDs in the Treatment of Alzheimer's Disease. 487-491	
158	. 2004 ,	2
157	Future directions in the treatment of Alzheimer's disease. 2004 , 13, 303-14	21
156	The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. 2004 , 13, 1469-81	39
155	Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid. 2004 , 89, 484-93	72
154	The age gap between patients in clinical studies and in the general population: a pitfall for dementia research. 2004 , 3, 627-30	86
153	Microglia as a potential bridge between the amyloid beta-peptide and tau. 2004 , 1035, 85-103	104
152	Inflammation and the degenerative diseases of aging. 2004 , 1035, 104-16	363
151	Neuroinflammatory perspectives on the two faces of Alzheimer's disease. 2004 , 111, 281-94	151

150	Reactive oxygen species mediate chloroquine-induced expression of chemokines by human astroglial cells. 2004 , 47, 9-20	62
149	Long-Term Outcomes of Galantamine Treatment in Patients With Alzheimer Disease. 2004 , 12, 473-482	26
148	Rivastigmine in Alzheimer Disease. 2004 , 12, 420-431	2
147	Using animal models to determine the significance of complement activation in Alzheimer's disease. 2004 , 1, 18	13
146	PPARGgamma, neuroinflammation, and disease. 2004 , 1, 5	32
145	Inflammatory processes and Alzheimer's disease. 2004 , 4, 793-8	20
144	Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. 2005 , 19, 29-36	80
143	Neurodegeneration. 2005 , 335-355	
142	Diagnosis and Treatment of Alzheimers Disease. 2005 , 5, 5-13	14
141	Inhibition of Brain Phospholipase A2 by Antimalarial Drugs: Implications for Neuroprotection in Neurological Disorders. 2005 , 2, 379-392	2
140	The role of inflammation in Alzheimer's disease. 2005 , 37, 289-305	547
139	Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics. 2005 , 22 Suppl 1, 1-26	28
138	A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. 2005 , 30, 1204-15	332
137	Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. 2006 , 14, 561-72	195
136	Current pharmacotherapy for Alzheimer's disease. 2006 , 57, 513-33	243
135	. 2006 ,	3
134	Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. 2006 , 9, 271-6	203
133	Alzheimer's Disease and Other Disorders Associated With Dementia. 266-298	1

132	Drug discovery in dementia: the role of rodent models. 2006 , 5, 956-70	158
131	Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease. 2006 , 1, 20-31	27
130	High-sensitivity C-reactive protein and cognitive function in older women. 2006 , 17, 183-9	54
129	Frailty of older age: the role of the endocrine-immune interaction. 2006 , 12, 3147-59	43
128	Therapeutic perspectives in Alzheimer's disease. 2006 , 1, 119-27	20
127	Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. 2006 , 12, 4337-55	36
126	Emerging therapeutics for Alzheimer's disease. 2006 , 6, 695-704	27
125	Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. 2007 , 5, 232-43	44
124	Current therapeutic options for Alzheimer's disease. 2007 , 8, 550-8	42
123	Low dose aspirin and cognitive function in the women's health study cognitive cohort. 2007 , 334, 987	62
122	1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. 2007 , 323, 822-30	74
121	Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. 2007 , 189-93	96
120	Determinants of platelet activation in Alzheimer's disease. 2007 , 28, 336-42	62
119	Management of mild to moderate Alzheimer's disease and dementia. 2007 , 3, 355-84	58
118	Pharmacological Mechanisms in Alzheimer's Therapeutics. 2007 ,	1
117	Neuropsychiatric Disorders An Integrative Approach. 2007 ,	4
116	Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. 2007 , 14, e1-26	400
115	Pro-inflammatory conditions promote neuronal damage mediated by Amyloid Precursor Protein and decrease its phagocytosis and degradation by microglial cells in culture. 2007 , 26, 153-64	38

114	Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. 2007 , 64, 1403-18	80
113	Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. 2008 , 39, 1-16	270
112	An aspirin a day for Alzheimer's disease?. 2008 , 7, 20-1	3
111	Inflammaging as a prodrome to Alzheimer's disease. 2008 , 5, 51	191
110	Imaging microglial activation in Alzheimer's disease: what does it mean?. 2008 , 64, 833-4	1
109	Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. 2008 , 16, 999-1009	37
108	Blueberry opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activation protein kinase. 2008 , 11, 891-901	35
107	No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. 2008 , 3, e1475	102
106	Tarenflurbil protection from cytotoxicity is associated with an upregulation of neurotrophins. 2008 , 15, 397-407	17
105	Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. 2008 , 14, 1419-27	108
104	The inflammatory hypothesis of Alzheimer disease: dead or alive?. 2008 , 22, 4-5	10
103	Intrathecal corticosteroids might slow Alzheimer's disease progression. 2008 , 4, 831-3	8
102	An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. 2009 , 18, 1147-68	75
101	Neuronal death in Alzheimer's disease and therapeutic opportunities. 2009 , 13, 4329-48	71
100	An update on treatment and prevention strategies for Alzheimer's disease. 2009 , 9, 368-76	32
99	Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial. 2009 , 57, 797-805	52
98	Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. 2009 , 109, 4885-910	282
97	A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. 2009 , 21, 102-10	108

96	Current treatment and recent clinical research in Alzheimer's disease. 2010 , 77, 3-16	55
95	Naturally occurring phytochemicals for the prevention of Alzheimer's disease. 2010 , 112, 1415-30	255
94	Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. 2010 , 114, 1261-76	32
93	Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?. 2010 , 2,	95
92	Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. 2010 , 24, 383-8	27
91	Disease progression meta-analysis model in Alzheimer's disease. 2010 , 6, 39-53	130
90	Current and emerging drug treatment options for Alzheimer's disease: a systematic review. 2011 , 71, 2031-65	155
89	Lipoxin A4 inhibits the production of proinflammatory cytokines induced by β amyloid in vitro and in vivo. 2011 , 408, 382-7	39
88	Frontiers in Alzheimer's disease therapeutics. 2011 , 2, 9-23	20
87	Function and comorbidities of apolipoprotein e in Alzheimer's disease. 2011 , 2011, 974361	28
86	Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology. 2011 , 10, 57-67	31
85	Current approaches and future directions of gene therapy in Alzheimer's disease. 2011 , 5, 159-168	1
84	Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial. 2011 , 15, 720-4	36
83	Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. 2012 , 2, a006395	48
82	Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies. 2012 , 8, 407-16	10
81	Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits. 2012 , 7, 245-59	14
80	Dopamine induces apoptosis in APP ^{swe} -expressing Neuro2A cells following Pepstatin-sensitive proteolysis of APP in acid compartments. 2012 , 1471, 102-17	15
79	Study protocol: EXERCISE and cognition in sedentary adults with early-ONset dementia (EXERCISE-ON). 2012 , 12, 75	12

78	Pharmacokinetic and ulcerogenic studies of naproxen prodrugs designed for specific brain delivery. 2012 , 35, 523-30	11
77	Are inflammatory profiles the key to personalized Alzheimer's treatment?. 2013 , 3, 343-351	3
76	Molecular links between Alzheimer's disease and diabetes mellitus. 2013 , 250, 140-50	132
75	Two Challenge and Rechallenge Episodes of Chloroquine-Induced Psychotic Mania in a Patient with Rheumatoid Arthritis. 2013 , 38, 177-179	2
74	Delivery of Polymeric Nanoparticles to Target Vascular Diseases. 2014 , 3,	9
73	Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. 2014 , 275, 251-83	437
72	Antiphospholipid antibodies as biomarkers in psychiatry: review of psychiatric manifestations in antiphospholipid syndrome. 2015 , 3, 25452	6
71	Chloroquine-containing compounds: a patent review (2010 - 2014). 2015 , 25, 1003-24	19
70	Alzheimer's disease clinical trials: past failures and future opportunities. 2015 , 5, 297-309	11
69	Neuroinflammation in Alzheimer's disease. 2015 , 14, 388-405	2760
68	Adverse events and dropouts in Alzheimer's disease studies: what can we learn?. 2015 , 11, 24-31	6
67	Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy. 2015 , 302, 103-11	118
66	The Rationale for Insulin Therapy in Alzheimer's Disease. 2016 , 21,	11
65	Targeting innate immunity for neurodegenerative disorders of the central nervous system. 2016 , 138, 653-93	87
64	Biology of Neuroinflammation: A Common Denominator in Brain Pathologies. 2016 , 1-16	1
63	Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics. 2017 , 17, 17-32	49
62	Neuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimer's disease. 2017 , 322, 269-279	35
61	Targeting Neuroinflammation to Treat Alzheimer's Disease. 2017 , 31, 1057-1082	129

60	Indomethacin Increases Neurogenesis across Age Groups and Improves Delayed Probe Trial Difference Scores in Middle-Aged Rats. 2017 , 9, 280	8
59	Past and Future of Drug Treatments for Alzheimer's Disease. 2018 , 57, 30	4
58	Anti-neuroinflammatory Potential of Natural Products in Attenuation of Alzheimer's Disease. 2018 , 9, 548	107
57	Peptides as Potential Therapeutics for Alzheimer's Disease. 2018 , 23,	32
56	Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?. 2018 , 17, 919-925	21
55	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. 2018 , 38, 653-671	152
54	Response to: 'Chronic hydroxychloroquine exposure and the risk of Alzheimer's disease' by Lai. 2021 , 80, e106	
53	Hydroxychloroquine antiparkinsonian potential: Nurr1 modulation versus autophagy inhibition. 2019 , 365, 82-88	10
52	Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer's disease: a population-based cohort study. 2019 , 78, 279-282	8
51	Response to: 'Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer's disease' by Lee. 2019 , 78, e138	2
50	Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. 2020 , 11, 562777	7
49	Drug repurposing for Alzheimer's disease: and investigation of FDA-approved drugs as acetylcholinesterase inhibitors. 2020 , 1-15	3
48	Alzheimer's disease: from basic science to precision medicine approach. 2020 , 2, e000079	9
47	Drug repositioning and repurposing for Alzheimer disease. 2020 , 16, 661-673	44
46	Hydroxychloroquine safety: A meta-analysis of randomized controlled trials. 2020 , 36, 101812	12
45	Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae. 2020 , 61, 597-606	17
44	What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials. 2020 , 155, 120-136	16
43	Pharmacological approaches to mitigate neuroinflammation in Alzheimer's disease. 2020 , 84, 106479	49

42	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer’s Disease. 2020 , 11, 456	87
41	Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials. 2021 , 77, 13-24	9
40	Clinical trials of promising apoptosis modulating drugs. 2021 , 329-391	1
39	Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs. 2021 , 40, 1221-1231	6
38	Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. 2021 , 58, 106-117	21
37	Hydroxychloroquine Increased Anxiety-Like Behaviors and Disrupted the Expression of Some Related Genes in the Mouse Brain. 2021 , 12, 633112	1
36	Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls. 2021 , ,	4
35	Tackling Alzheimer’s Disease with Existing Drugs: A Promising Strategy for Bypassing Obstacles. 2021 , 28, 2305-2327	0
34	A systematic review and meta-analysis of the safety of Hydroxychloroquine in a randomized controlled trial and observational studies. 2021 ,	
33	Potential long-term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans. 2021 ,	2
32	The Role of Adaptive and Innate Immunity in Alzheimer’s Disease. 2021 , 213-232	
31	Potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer’s disease. 2021 , 90, 102196	3
30	Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Derived A β 2-Lowering Molecules for Treatment and Prevention of Alzheimer’s Disease (AD). 2007 , 167-193	1
29	Functional Imaging and Psychopathological Consequences of Inflammation in Alzheimer’s Dementia. 2005 , 75-83	1
28	The Role of Rodent Models in the Drug Discovery Pipeline for Dementia. 2011 , 35-49	1
27	The Involvement of A β in the Neuroinflammatory Response. 2007 , 52-82	1
26	Assessment of Hydroxychloroquine and Chloroquine Safety Profiles: A Systematic Review and Meta-Analysis. 2020 ,	5
25	Innate immunity, local inflammation, and degenerative disease. 2002 , 2002, re3	43

24	Mechanism-based treatments for Alzheimer's disease. 2009 , 11, 159-69	13
23	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. 2017 , 21, 1-192	19
22	Alzheimer's Disease: Search for Therapeutics. 2003 , 743-777	1
21	βAmyloid Therapeutic Strategies for Alzheimer's Disease.	0
20	Entzündung und Alzheimer Krankheit. 2007 , 20, 39-45	
19	Aging and Cognitive Decline: Neuroprotective Strategies. 2007 , 245-268	
18	Inhibitors of Phospholipases A2 and Their Use for the Treatment of Neurological Disorders. 2007 , 275-319	
17	Alzheimer's Disease: Risk Factors and Preventive Strategies. 2010 , 271-280	
16	The Current Status of Alzheimer's Disease Treatment. 2012 , 117-161	
15	Alzheimer Disease. 2013 ,	
14	Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings. 2014 , 185-211	
13	A Concept to Improve Care for People with Dementia. 2019 , 603-618	
12	Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions. 2021 , 10, 294	0
11	Hydroxychloroquine increased psychiatric-like behaviors and disrupted the expression of related genes in the mouse brain.	
10	Progress update: Pharmacological treatment of Alzheimer's disease. 2007 , 3, 569-78	18
9	Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors.. 2021 , 7, e12202	2
8	Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease: Nested Case-Control Study of People With Rheumatoid Arthritis.. 2022 ,	1
7	Virus-Induced Membrane Fusion in Neurodegenerative Disorders.. 2022 , 12, 845580	0

- 6 Microglial activation in Alzheimer's disease: The role of flavonoids and microRNAs.. **2022**, 2
- 5 Combined drug triads for synergic neuroprotection in retinal degeneration. **2022**, 149, 112911 1
- 4 DataSheet_1.pdf. **2020**,
- 3 DataSheet_2.pdf. **2020**,
- 2 Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study. **2022**, 22, 0
- 1 Hydroxychloroquine lowers Alzheimer's disease and related dementias risk and rescues molecular phenotypes related to Alzheimer's disease. 0